BioCentury
ARTICLE | Clinical News

GTI-2040: Phase I/II ongoing

September 19, 2005 7:00 AM UTC

A steering committee recommended continuation of the Phase II portion of an NCI-sponsored, dose-escalation, Canadian Phase I/II trial to evaluate GTI-2040 plus Taxotere docetaxel from sanofi-aventis ...